Results 11 to 20 of about 31,541 (206)

Inadequate Lopinavir Concentrations With Modified 8-hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV [PDF]

, 2023
Background: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated ...
Mulenga, Veronica, McIlleron, Helen, Chungu, Chalilwe, Choo, Louise, Tembo, Chimuka H, LeBeau, Kristen, Weisner, Lubbe, Crook, Angela, Gibb, Diana, Chabala, Chishala, Turkova, Anna, Zimba, Kevin, Zyambo, Khozya, Lungu, Joyce, SHINE trial team, Kapasa, Monica   +15 more
core   +6 more sources

The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration [PDF]

, 2011
The relationship between lopinavir plasma concentration and the magnitude of lipid elevation after initiation of lopinavir/ritonavir-containing antiretroviral therapy is unclear.
Burger, David M., Sven A Danner, Michiel A van Agtmael, Veldkamp, Agnes I., van Vonderen, Marit G. A., Reiss, Peter, Agnes I Veldkamp, Danner, Sven A., Bierman, Wouter F. W., David M Burger, Peter Reiss, Wouter FW Bierman, van Agtmael, Michiel A., Marit GA van Vonderen   +13 more
core   +3 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Use of B‐complex vitamins and olfactory training for treating COVID‐19–related anosmia

Clinical Case Reports, 2021
A 42‐year‐old male patient was diagnosed with coronavirus disease 2019. His symptoms improved 2 weeks after lopinavir therapy (800 mg/day). However, he was subsequently diagnosed with complete anosmia.
Yethindra Vityala, Aliya Kadyrova, Shirin Zhumabaeva, Aizhan Bazarbaeva, Sagynali Mamatov   +4 more
doaj   +1 more source

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Терапевтический архив, 2021
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of ...
Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, Svetlana N. Orlova, Elena P. Tikhonova, Vladimir A. Petrov, Oleg V. Malinin, Natalia V. Kolaeva, Elena V. Volchkova, Nina N. Kanshina, Vladimir P. Chulanov   +17 more
doaj   +1 more source

Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans—In Silico, In Vitro and In Vivo Approaches

Journal of Fungi, 2021
The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen Candida albicans ...
André L. S. Santos, Lys A. Braga-Silva, Diego S. Gonçalves, Lívia S. Ramos, Simone S. C. Oliveira, Lucieri O. P. Souza, Vanessa S. Oliveira, Roberto D. Lins, Marcia R. Pinto, Julian E. Muñoz, Carlos P. Taborda, Marta H. Branquinha   +11 more
doaj   +1 more source

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)

South African Journal of Science, 2015
Currently, the treatment of choice of HIV/AIDS in South Africa is the multidrug combination regimen known as HAART (highly active antiretroviral treatment).
Gbenga A. Adefolaju, Katherine E. Theron, Margot J. Hosie   +2 more
doaj   +1 more source

Docking and Molecular Dynamic Simulations Study to Search Curcumin Analogue Compounds as Potential Inhibitor Against SARS-CoV-2: A Computational Approach

Jurnal Kimia Sains dan Aplikasi, 2021
Coronavirus is a pandemic in the world. It requires researchers and scientists to work hard to find a vaccine or drug to inhibit the development of the coronavirus. Many drugs have been used, such as remdesivir, lopinavir, and chloroquine.
Neni Frimayanti, Adel Zamri, Yum Eryanti, Noval Herfindo, Veza Azteria   +4 more
doaj   +1 more source

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV [PDF]

, 2008
Background: Prior attempts to reduce the number of drugs needed to maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral drugs have been unsuccessful.
Pulido Ortega, Federico, Rubio García, Rafael, Norton, Michael   +2 more
core   +1 more source

Lopinavir pharmacokinetics in COVID-19 patients [PDF]

, 2020
International audienceThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. Therapeutic solutions are currently being tested for COVID-19, the SARS-CoV-2-associated pneumonia.
Gaborit, Benjamin, Grégoire, Matthieu, Lecomte, Raphaël, Le Turnier, Paul, Canet, Emmanuel, Veyrac, Gwenaelle, Boutoille, David, Bellouard, Ronan, Raffi, François, Imbert, Berthe-Marie   +9 more
core   +1 more source